

# Acute myeloid leukaemia - therapy - past, present and future

Paul Faduola<sup>1</sup>, Alan Hakim, Juli Mansnérus<sup>1</sup>, Atsuko Imai<sup>1</sup>, Rob O'Neill<sup>2</sup>

<sup>1</sup> University of Edinburgh.

<sup>2</sup> Edinburgh Cancer Research Centre.

\* Corresponding Author:

✉ paul@nordicalagos.org



This article can also be found as part of the book

"New therapies for Acute Myeloid Leukaemia" that can be purchased in **Amazon**.

## Abstract

Acute myeloid leukemia (AML) is characterized by genetic aberrations and a variable response to therapy which has made treatment of AML challenging. The objective of this paper is to review conventional treatments and their development, phase I-III clinical trials of new agents, novel pathways where future interventions may have therapeutic potential, and clinical trial assessment in AML. This study showed that a detailed understanding of the molecular changes associated with chromosomal and genetic abnormalities is necessary to pilot new therapy design. Although several deregulated proteins and genes have been identified, their diversity among AML patients have made it difficult to identify a single substance that can hit these diverse targets. New agents have shown promise but there remains a huge need to be met for effective and targeted therapies to be successful.

## Introduction

Chemotherapy, irradiation and haematopoietic stem cell transplantation (HSCT) are now standard therapies in acute myeloid leukaemia (AML) (1). Chemotherapies, anti-metabolites blocking DNA/RNA synthesis, have been a corner stone for three decades. However they have numerous side effects and limitations in efficacy (2). HSCT is similarly challenged by toxicity and efficacy(3). The overall 5-year survival from AML remains poor, particularly in adults and in the elderly (4). Genomic and proteomic technologies have provided opportunities for development of targeted therapies through improved understanding of molecular biology, and better characterization of AML subgroups (5-7). New agents are in phase I-III clinical trials. Several have been rejected as ineffective or unsafe but a small number have demonstrated potential (8). However, none stand alone as mono-therapies or more effective than standard chemotherapy in low- and intermediate-risk patient groups, and continue to be assessed for adjuvant properties. This paper will review conventional treatments and their development, phase I-III clinical trials of new agents, novel pathways where future interventions may have therapeutic potential, and clinical trial assessment in AML.

## Drug therapies

### Chemotherapy

Chemotherapy protocols are divided in to two stages. The first, 'Induction', aims to reduce diseased cells to undetectable levels (complete remission (CR)). The second, 'Consolidation' (or post-remission), is the elimination of residual undetectable disease to achieve a cure (9-10). In relapse treatment may revert to Induction, though there may be need to lower dosage depending on individual circumstance e.g., toxicity of previous therapy and level of morbidity (11). HSCT might be undertaken if Induction chemotherapy fails or a patient relapses despite Consolidation therapy(12). It may also be undertaken as first-line therapy alongside chemotherapy for patients with high-risk disease e.g., cytogenetic group, underlying myelodysplasia (MDS), or secondary and therapy-related AML (13).

Successful intervention is hampered by cytogenetic heterogeneity, toxicity (Box 1), multi-drug resistance (MDR), and age (14). Older patients (age >60) respond less well. In part this is due to the presence of co-morbidities but also greater association with MDS and secondary AML. In addition, clinicians have had a tendency to view therapy as palliative in older age groups, preferring to avoid toxicity, and studies have been

biased by exclusion of these groups. In many respects it has been this poor outlook for elderly and secondary AML that has driven new agents through phase I and II trials recently. Although the majority of patients under 60 years reach CR after intensive chemotherapy(15-16), relapse free survival (RFS) is uncommon. The 10-year overall (OS) and event free (EFS) survival for children/adolescents after Induction therapy is 55-65%. However, in adulthood only 20-40% of all patients gain disease-free survival (DFS) of >5 years from chemotherapy alone.

Radiation therapy for AML is generally used only if there is central nervous system involvement and no response to systemic and/or intrathecal chemotherapy (17). It may also be used in preparation for HSCT.

**Box 1.** Common side effects / consequences of chemothera.

Bone marrow suppression: Anaemia, Bleeding/Bruising, Infection  
Hair loss  
Nausea, Vomiting, Diarrhoea  
Loss of taste  
Mucosal ulcers (Mouth, Oesophagus)  
Fatigue  
Dry skin and brittle nails  
Headaches, dizziness  
Peripheral neuropathy (usually non-reversible)  
Loss of hearing  
Increased risk of secondary cancer  
Loss of fertility, increased risk of foetal developmental abnormalities

**Table 1.** Induction Protocols with Conventional Chemotherapies

| Principle   | Agent / Study   | Comment   | Refs  |
|---|---|---|---|
| Standardising cytotoxic therapy                                   | Childhood (under 18 years of age)<br>Mitoxantrone or Daunorubicin in combination with Cytarabine and Etoposide.   | The AML 12 trial showed a 10-year EFS of 54%, OS of 63% and relapse of 35% with no difference in CR between Mitoxantrone and Daunorubicin. Whilst Mitoxantrone showed a small benefit in a lower relapse rate this did not confer any OS advantage. The trial also showed no benefit of 5 over 4 cycles of treatment.   | 18-21<br><br>22-25  |
|   | Adults (age 18 years and above)<br>An Anthracycline for 3 days (Either: Daunorubicin, Idarubicin, or Mitoxantrone), in combination with 7 days of Cytarabine. | No other intervention shown to be better.<br><b>Younger Adults - 18-60yrs:</b><br>Treatment should be started immediately after diagnosis<br>CR in 60-80%<br><br><b>Older patients - 60-74yrs:</b><br>CR in 50%, however with adverse cytogenetics (Chapter 2) CR drops to 30% and Overall survival (OS) 5%.<br><br>Timing of starting therapy in older patients should be individualized and based on comorbidities.<br><br><b>Patients &gt;75yrs:</b><br>An alternative should be sought. Low dose Cytarabine is associated with longer survival in cytogenetically normal and mutated NMP1 (Chapter 2) case. | 26-28   |
|   | Comparative trials of Anthracyclines  | Randomised studies have compared Daunorubicin with Idarubicin, Aclarubicin, Amsacrine, and Mitoxane.  | No agent appears to be superior to Daunorubicin with respect to OS.<br><br>They are equitoxic in older patients (>60years). |
| High vs Low Dose  | High Dose Cytarabine (HiDAC)  | No CR advantage of HiDAC over low dose. Not recommend as toxicity increased.<br><br>HOVON/SAKK/AML CG studies suggest Daunorubicin can be dose intensified in up to age 65 yrs with improved CR and survival.   | 36-41<br><br>41   |
| Additional cytotoxic agents or Modulators of Multidrug Resistance | Thioguanine, Etoposide, Fludarabine, Topotecan  | No increase in response rate.   | 42-47   |
| Priming with growth factors to sensitize leukaemic cells          | HOVON and SAKK studies  | Priming with G-CSF significantly increased DFS and OS respectively.   | 48-51   |
|   | AML CG study  | Did not show impact on OS.  |   |
|   | ALFA study  | GM-CSF increased the CR but no effect on OS.  |   |

**‘Old dogs, new tricks’**

The focus of chemotherapy clinical trials research over the last 15 years has been to identify:

- i.** The most appropriate dose and frequency of administration,
- ii.** The efficacy of combination therapies,
- iii.** Whether certain agents are better than others by direct comparison,
- iv.** New formulations of established drugs (e.g., Liposomal drugs), and
- v.** The value of adjunct therapies - facilitating effectiveness of chemotherapy and/or combating MDR.

**Tables 1** (Induction) and **Table 2** (Consolidation) are a synthesis of trial literature demonstrating the development of chemotherapies over the last decade and a half, with reference to differences between age groups, and to CR and OS. Various Consolidation strategies have been evaluated including intensive conventional chemotherapy, prolonged maintenance treatment, and high-dose therapy followed by autologous or allogeneic HSCT.

The encapsulation of drugs in liposomes has led to new ways of more effectively delivering chemotherapy with a reduction

in toxic side effects. Liposomal Daunorubicin has been shown in a Phase III trial to be as effective as normal Daunorubicin but better tolerated (60). The agent CPX-351 is a liposomal fixed combination of Daunorubicin and Cytarabine. Recent Phase I/II trials suggest CPX-351 to have an acceptable safety profile for use in older and previously untreated patients (61,62). Similarly, Elacytarabine, a derivative of Cytarabine but one that inhibits both DNA and RNA synthesis, has been demonstrated to be efficacious at least to the same degree as other agents, but with less toxicity in recent Phase II trials of patients in relapse requiring salvage therapy (63).

Given poor outcomes despite major advances in understanding best use of conventional chemotherapeutic agents, the need to develop novel therapies with different anti-leukaemic mechanisms is paramount. New agents entering the clinical arena include:

**New Molecular Targeted Therapies**

- i.** Monoclonal antibodies,
- ii.** Tyrosine kinase, and farnesyltransferase inhibitors,
- iii.** Cell growth blockers,
- iv.** Immunotherapies,
- v.** MDR1 inhibitors, and
- vi.** Peptide vaccines.

**Table 2.** Consolidation Chemotherapy.

| Principle  | Agent   | Comment  | Ref            |
|--|---|--|----------------|
| High Dose Cytarabine (HiDAC)                               | Cytarabine  | Young Adults - 18-60yrs<br>The CALGB study showed HiDAC to be superior to lower doses - but, restricted in success to Core Binding Fusion-Gene AML (Chapter 2) and to a lesser degree Cytogenetically Normal AML.      | 52             |
|  |   | Other cytogenetic abnormalities are not affected by HiDA.  | 53             |
| Comparative trials with HiDAC                              |   | Prolonged consolidation / multi-agent chemotherapy no better than HiDAC.   | 54-56          |
| Prolongation of Maintenance therapy                        |   | No benefit in remission duration or OS compared to autologous HSCT in non-APL AM.  | See HSCT below |
| Older Patients 60yrs or more. Consolidation therapy trials | Cytarabine vs Cytarabine + Mitoxantrone.  | No clear recommendations can be given.<br>CALGB study - found no differences.  | 57             |
|  | Cytarabine + Anthracycline or Thioguanine                                       | AMLG92 trial - older patients benefited with longer remission - particularly effective in AML1-ETO AML (Chapter 2).<br>AML-12 study also showed benefit in Childhood of consolidation with Idarubicin and Thioguanine. | 58<br>18       |
|  | 6 cycles of Daunorubicin or Idarubicin + Cytarabine vs 1 standard consolidation | French ALFA 9803 - 6 cycles gave superior DFS and OS   | 35             |
|  | Combination dosing of Idarubicin and Etoposide                                  | AMLSG AML HD98B trial  | 59             |

**Table 3.** Molecularly Targeted Therapy in Clinical Trials and Practice.

| Class / Agent  | Comment  | Refs           |
|--|--|----------------|
| Monoclonal Antibodies:<br>Gemtuzumab - Ozogamicin  | Gemtuzumab is a humanised anti-CD33 antibody, approved in older patients who are not considered candidates for other cytotoxic therapies.<br>Remission rates in 15% to 35% of older patients who have relapsed.<br>Addition to standard induction therapy in younger adults led to a 91% CR rate.  | 64-68          |
| Lintuzumab (SGN-33)<br>Bevacizumab   | This trial (a study in combination with Cytarabine) was discontinued in 2011 as mid trial results showed no additional benefit.<br>Bevacizumab is directed against the vascular endothelial growth factor receptor (VEGFR). It also promotes survival of multipotential haematopoietic stem cells. It was the first angiogenesis inhibitor approved in 2004 by the FDA. Following a phase II trial demonstrating 33% CR further studies are now warranted.   | 69             |
| FLT3 Tyrosine kinase inhibitors:<br>Midostaurin<br>Lestaurtinib<br>Sunitinib<br>Tandutinib<br>Semaxinib<br>Sorafenib | Several FLT3-selective tyrosine kinase inhibitors have in vitro cytotoxicity to leukaemia cells.<br>Pilot studies combining intensive Induction and Consolidation therapy with FLT3 inhibitors have shown promising response rates in patients with FLT3 mutations.  | 70-74          |
| KIT Tyrosine kinase inhibitors:<br>Imatinib<br>Dasatinib<br>Axitinib   | Imatinib competitively binds to the ATP-binding site of the tyrosine kinase Bcr-Abl, and targets KIT. It is the choice of treatment in Chronic Myeloid Leukaemia. Unfortunately the response rate was only 11% in a phase II trial of KIT positive AML patients treated with low-dose Cytarabine (LDAC) and Imatinib. However, it was no more responsive than LDAC, showing that LDAC monotherapy was just as good a 'blanket' treatment in patients unselected for the KIT molecular marker.<br>Similarly Axitinib, which also inhibits VEGFR (Monoclonals above), has entered phase II study but not demonstrated any clinical efficacy.<br>Dasatinib has been studied in vitro and its potential clinical benefit remains to be demonstrated. | 75, 76         |
| mTOR kinase inhibitors:<br>Rapamycin<br>Everolimus<br>Temsirrolimus<br>Deforolimus                                   | mTOR is a complex protein and a central regulator of many signalling pathways controlling cell division, metabolism and angiogenesis. There is evidence that its effect is manifest through a P13K/Akt pathway that is heavily dysregulated in haematological malignancies. Following phase II demonstration of efficacy and tolerability but minimal value as monotherapies, several agents are now being studied in combination with conventional therapies e.g., AML-12 trial (see below).  | 77,78          |
| Farnesyltransferase inhibitors:<br>Tipifarnib<br>Lonafarnib<br>BMS-214662  | These agents can be given orally.<br>They are in the early stages of phase I/II study.<br>Tipifarnib in combination with Etoposide has recently been shown to achieve 50% CR in very poor risk older patients, which is extremely encouraging.<br>Lonafarnib has limited activity in older patients where focus was on treating secondary AML.<br>Four out of 9 patients entered CR in a phase 1 study of BMS-214662; sufficient evidence to recommend a phase II trial.   | 79<br>80<br>81 |
| Hypomethylating (nucleosidase analogue) agents:<br>Azacitidine and Decitabine  | These act by inhibition of ribonucleotide reductase and DNA polymerase, inducing apoptosis.<br>Two demethylating agents, the Cytosine analogues Azacitidine and Decitabine, have been approved for the treatment of MDS (Chapter 1).<br><br>Azacitidine prolonged OS compared with conventional care regimens in patients with intermediate- or high-risk MDS (of which 1/3rd had AML). 2-year OS was 50% with Azacitidine compared with 16% with conventional treatment regimens.<br>Azacitidine has been approved for older patients with AML with 20% to 30% blasts.<br><br>Decitabine (Dracogen) has recently been rejected by the Federal Drug Administration (FDA) for its 'unfavourable risk/benefit profile'.                            | 82-86          |

|   |   |                  |
|---|---|------------------|
| <p>Other Nucleosidase Analogues:<br/>Clofarabine<br/>Troxacitabine<br/>Sapacitabine</p>                         | <p>Clofarabine is a purine nucleoside analogue synthesized to combine the most favourable pharmacokinetic properties of Fludarabine and Cladribine. Phase II trials are required but an initial study (hindered by hepatotoxicity) showed a 44% OS and 21% CR in elderly patients who were otherwise unfit for intensive chemotherapy. After some success in small phase I and II studies a larger scale trial of Troxacitabine was terminated in 2006 after 6 months with only 10-15% of patients achieving CR. Sapacitabine is now in phase III trial. It is an oral agent that may be particularly useful in untreated elderly patients, first relapse, or secondary AML following MDS treatment.</p>  | <p>87-91</p>     |
| <p>DNA alkylating agents:<br/>Laromustine (Cloretazine)</p>   | <p>Laromustine was shown to have a CR of 35% compared to 19% for Cytarabine in a phase I study of patients with relapse or refractory disease. However the OS in both groups was the same.</p>  | <p>92</p>        |
| <p>Immunomodulators:</p>  | <p>The agent Ceplene (Histamine) has been licensed for use with Interleukin-2 (IL-2) in Europe but not in the UK or USA. The FDA recently advised that the Phase III trial that demonstrated efficacy for maintenance of remission be re-opened with a comparator arm of IL-2 monotherapy despite 5 previous studies showing IL-2 monotherapy to be ineffective.</p>  | <p>93</p>        |
| <p>Histone Deacetylators:<br/>Panobinostat<br/>Vorinostat<br/>Entinostat<br/>Mocetinostat<br/>Valproic Acid</p> | <p>Phase I and II studies have not shown these agents to have any clinical activity as monotherapies. Further research is needed to determine whether they have any synergistic effects with other cytotoxics.</p> <p>A phase II clinical trial of Azacetidine, Valproic acid and All Trans Retinoic Acid has recently demonstrated improved CRs (20-30%), albeit still short OS in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.</p>   | <p>94,95</p>     |
| <p>Multidrug Resistance (MDR) Modulators:<br/>Valspodar<br/>Zosuquidar</p>                                      | <p>Several MDR modulators have been studied. All are lipophilic and include the immunosuppressant Cyclosporine. Valspodar is potent Cyclosporine derivative without immunosuppressant effect or the renal toxicity of Cyclosporine. Unfortunately the outcome of the phase III AML 14 trial showed a poorer outcome in the Valspodar treated group. Phase I studies of Zosuquidar (blocks drug clearance through P-gp transporters) have shown it to be tolerable and have significant effect on clearance of Cytarabine and Daunorubicin in vitro. It now needs to enter phase II trials to establish whether it has any clinical effectiveness as an adjuvant therapy.</p>  | <p>96<br/>97</p> |
| <p>Vaccines:</p>  | <p>The basis of peptide vaccination is the observation that leukaemia cells (LCs) can act as antigen-presenting cells (APCs). Through HLA class I and II pathways peptides are presented to CD4+ helper and CD8+ cytotoxic T lymphocytes. Peptides can be introduced in to LCs differentiated from normal cells by surface markers (Chapter 3). The LCs then acting as APCs present a peptide to T cells in a more efficient manner than AML blasts might do alone. These lymphocytes become activated and proliferate. Once such primed T cells encounter the same epitope peptide on the surface of an AML blast, the malignant cell can be lysed. These have looked at the impact of Proteinase 3, RHAMM and WT1 interventions. Table 4 is devoted to this area given the number of specific trials. The WIN Study is a Phase II trial. Recruitment closes in July 2012. This is looking at responses to influence expression of gene fusion associated with WT1 .</p> | <p>98</p>        |
| <p>Chromosome 5 abnormalities:</p>  | <p>The Len5 study closed to recruitment in Nov 2011 and is on-going. It is exploring the efficacy of Lanalidomide (Revlimid) in AML subgroups associated with Chromosome 5 abnormalities.</p>   |                  |

**Table 4.** Peptide Vaccination in AML.

| Antigen              | Peptide sequence/amount  | Patients included in the trial per entity                                | Clinical status before vaccination      | Ref     |
|----------------------|--|--|---|---------|
| Proteinase 3         | Pos. 169-177 VLQELNVTV (designated 'PR1') 0.25, 0.5 or 1.0 mg sc. q3wks x 3              | 42 AML, 13 CML, 11 MDS   | 53 active disease, 13 CR                | 99,100  |
| RHAMM                | Pos. 165-173 ILSLELMKL (designated 'R3') 300 $\mu$ g sc. q2wks x 4                       | 2 AML, 4 MDS, 4 MM   | Limited tumour load or MRD              | 101     |
|                      | R3 peptide 300 $\mu$ g sc. q2wks x 4   | 6 B-CLL  | Early stage (Binet A)                   | 102     |
|                      | R3 peptide 1000 $\mu$ g q2wks x 4  | 1 AML, 5 MDS, 3 MM   | Limited tumour load or MRD              | 103     |
| WT1                  | Pos. 126-134 RMFPNAPYL 0.2 mg sc. q2wks x 4 then q28d up to 23 times (until progression) | 24 AML, 2 MDS  | 18/26 active disease, 8 CR              | 104,105 |
|                      | Pos. 235-243: CMTWNQMNL with modification CYTWNQMNL 0.3, 1.0 or 3 mg id. q2wks x 3       | 12 AML, totally 26 (including 2 breast cancer, 10 lung cancer and 2 MDS) | 12 CR                                   | 106     |
| WT1 and proteinase 3 | PR1 peptide 0.5 mg WT1. Pos. 126-134 0.2 mg sc. 1x                                       | 5 AML, 1 CML, 2 MDS  | 1 RARS, 2 RA, 4 CR (AML) and 1 (CML) CP | 107,108 |
|                      | PR3 and WT1 q2wks x 6  | 3 AML, 1 MDS   | <30% blasts in the BM                   | 109     |

Adapted from Scmitt M et al (98).

**Table 3** and **4** outline trials in this area. In the majority of cases these trials have small numbers of patients and/or have selected for more complex disease and non-responders.

On the whole the inhibition of deregulated transcriptional activity consequent on gene mutations has not led to therapeutic innovation; the exception to this is all-*trans*retinoic acid and arsenic trioxide in APL. Inhibition of tyrosine kinase activity, nucleoside analogues, and monoclonal targeting of the antigen CD33 have demonstrated some success but none of these agents are superior to the combination Induction and Consolidation highlighted in **Table 1** and **2**.

Combinations of novel and current therapies are currently being explored in multi-faceted/multi-centred trials. The AML-17 (recruitment from 2002 to 2014) is one such phase III study looking at:

- i. The best dose of Daunorubicin,
- ii. CEP-701, a new FTL3 inhibitor,
- iii. Everolimus (Afinitor) a signal transduction inhibitor that blocks the signalling protein mTOR,
- iv. The comparison of 2 chemotherapy treatments before HSCT,
- v. The comparison of 1 with 2 or more cycles of chemotherapy, and
- vi. The role of Arsenic Trioxide in non-APL AML.

**And in addition:**

- i. Clofarabine, a nucleoside analogue (see above), is being compared with other chemotherapies having been shown

- to have fewer side effects but similar efficacy to Fludarabine in the treatment for older patients considered unsuitable for induction chemotherapy, and
- ii. Studies will continue to look at the role of Gemtuzumab.

There does not appear to be a revolutionary step change in drug therapy on the horizon in the management of AML. Attention is focused on synergistic effects of combining conventional with novel targeted agents. Though targeting of leukaemic stem cells (LSC) by, for example, receptor specific small molecules and peptide vaccines would appear a reasonable approach, the similarities between LSC and normal stem cells is also a challenge. Currently the targeting of LSCs remains relatively non-selective and requires simultaneous interventions.

## Haematopoietic stem cell transplantation

The developmental milestones in stem cell therapy (SCT) from the 1950s from preclinical trials to the successful application in human transplantation in the late 1970s are shown in **Table 5**. These laid the foundation for many areas of stem cell research, as well as current HSCT practices.

Four sources of HSCT are available and each has its pros and cons (**Table 6**). The vast majority of clinical trials have been in allogenic and autologous stem cell transplants (SCT). Despite our learning of how best to use these therapies the challenges remain better techniques for cryopreservation,

**Table 5.** Developmental milestones in HSCT.

| Year | Development of Haematopoietic Stem Cell Transplantation                                      | Challenges   |
|------|--|--|
| 1949 | Spleen shielding experiment of Jacobson.   | Limited knowledge of radiation in immune-suppression   |
| 1957 | First human twin transplants for leukaemia.  | Relapse  |
| 1962 | Successful allogeneic transplants in dogs  | Understanding of human histo-compatibility   |
| 1968 | First successful allogeneic transplants in humans.   | Graft-vs-Host Disease (GVHD), limited understanding of details of human histocompatibility, lack of experience with the use of immunosuppressive drugs, and shortcomings in supportive care techniques |
| 1977 | Successful application of autologous marrow transplantation                                  | Lack of genetic markers, poor cryopreservation technology  |
| 1979 | Encouraging results in patients with acute myeloid leukaemia transplanted in first remission | GVHD and complications, Relapse, toxicity, and limited donor compatibility and availability.   |

**Table 6.** Pros, Cons and Challenges of the different types of HSCT.

| TYPE OF SCT                                 | PROS  | CONS   | CHALLENGES   |
|---|---|--|--|
| Allogeneic SCT                              | GVL effect represents one of the most powerful anti-leukaemia treatments.           | GVHD, Treatment-related mortality (TRM)  | Improving current sources of transplantation and incorporating novel therapies to mitigate TRM         |
| Autologous SCT                              | Immunologic compatibility between infused haematopoietic stem cell.                 | Absence of GVL which is crucial to achieving good outcome in SCT, shorter DFS  | Contaminated sample, elucidating autologous stem cell transplantation in conjunction with gene therapy |
| Umbilical Cord Blood                        | Greater availability, increase in eligible donors and decreased incidence of GVHD   | Decreased numbers of stem cells, increase graft failure and mortality.   | Overcoming cell dose limitation.   |
| Induced pluri-potent stem cells (Chapter 2) | Prospects to generate SC uncontaminated for autograft without ethical complications | Genomic instability, tumour formation, and the lengthy time requirements needed to obtain these cells via retrovirus development | Locating pluripotent stem cell sources without the need for reprogramming protein integration          |

identification and classification of genetic markers, and understanding the influence of SNPs (3), non-HLA genetics, and cytokine genes (110-112).

In patients with favourable- and intermediate-risk cytogenetics, autologous HSCT is an alternative Consolidation option to chemotherapy. It is not recommended in cases with high-risk cytogenetics (113-115). There is no evidence that this approach gives a better outcome in general, however it may be of advantage in cytogenetically normal and tandem repeat subsets of AML (116). The lowest relapse rates are observed following Consolidation with allogeneic HSCT. The benefit is in part attributable to a potent graft-versus-leukaemia (GVL)

effect (117). Meta-analyses of clinical trials comparing allogeneic HSCT versus Consolidation chemotherapies after first CR show a significant improvement in OS in intermediate- and high-risk AML (118-120). **Table 7** shows data from several studies in the 1990s. The DFS following Consolidation is in general superior for allogeneic vs autologous HSCT, and for HSCT vs chemotherapy. However OS rates were not significantly different in a number of these studies. Data from the 2000s in childhood disease is more compelling for favourable outcome of DFS and OS after allogeneic HSCT (**Table 8**).

It is important to consider the risks of treatment-related mortality (TRM). These range between 15-50% and may

**Table 7.** Comparative Disease Free Survival following Allogeneic HSCT, Autologous HSCT, and Chemotherapy for AML patients in first remission

| Study (date)         | Treatment    | No of pts | DFS | P value     | OS  | P value | Relapse | P value | Ref |
|----------------------|--------------|-----------|-----|-------------|-----|---------|---------|---------|-----|
| France (1989)        | Allo         | 20        | 66% | <0.004      |     |         | 18%     | <0.0002 | 121 |
|                      | Auto         | 12        | 41% |             |     |         | 50%     |         |     |
|                      | Chemotherapy | 20        | 16% |             |     |         | 83%     |         |     |
| Netherlands (1990)   | Allo         | 23        | 51% | NS          | 66% | 0.05    | 34%     | 0.03    | 122 |
|                      | Auto         | 32        | 35% |             |     |         | 60%     |         |     |
| EORTC/CIMEMA (1996)  | Allo         | 168       | 55% | significant | 59% | NR      | 27%     | NR      | 123 |
|                      | Auto         | 128       | 48% |             | 66% |         | 41%     |         |     |
|                      | Chemotherapy | 126       | 30% |             | 46% |         | 57%     |         |     |
| GOELAM (1997)        | Allo         | 88        | 44% | NS          | 53% | NS      |         |         | 124 |
|                      | Auto         | 86        | 44% |             | 50% |         |         |         |     |
|                      | Chemotherapy | 78        | 40% |             | 55% |         |         |         |     |
| US Intergroup (1998) | Allo         | 113       | 43% | NS          | 46% | 0.04    | 29%     |         | 125 |
|                      | Auto         | 116       | 34% |             | 43% |         |         |         |     |
|                      | Chemotherapy | 117       | 34% |             | 52% |         |         |         |     |
|                      | Allo         | 92        | 47% |             | 45% |         |         |         |     |
|                      | Auto         | 63        | 48% | NR          | 55% | NR      | 62%     |         |     |
| MRC (1998)           | Auto         | 190       | 53% | 0.04        | 57% | 0.2     | 37%     | <0.01   | 126 |
|                      | Chemotherapy | 191       | 40% |             | 45% |         | 58%     |         |     |

**Allo:** Allogeneic, **Auto:** Autologous, **NS:** not significant, **NR:** not reported, **DFS:** Disease Free Survival, **OS:** Overall Survival. Adapted from Blume and Thomas (127).

**Table 8.** Comparative outcome data in Childhood Trials of Allogeneic HSCT, Autologous HSCT, or Chemotherapy for AML

| Trial identification           | Risk groups                         | No of Patients   | DFS (%)                           | OS (%)   | Reference |
|--------------------------------|-------------------------------------|--|-----------------------------------|--|-----------|
| AML88                          | High risk                           | 17 allo<br>31 auto   | 74 (8 years)<br>74                |  | 128       |
| CCG2891                        | Not stated                          | 177 auto<br>179 chemo<br>181 allo<br>P-value                                   | 42 (8 years)<br>47<br>55<br>0.01  | 48 (8 years)<br>53<br>60<br>0.05                   | 129       |
| MRC10                          | Low 28%,<br>Medium 52%,<br>High 20% | 85 donor<br>230 no donor<br>P-value<br><br>50 auto<br>50 no therapy<br>P-value | 68<br>46<br>0.02                  | 70 (7 years)<br>60<br>0.10<br><br>70<br>59<br>0.20 | 130       |
| CCG 251, 213, 2861, 2891, 2941 | Not stated                          | 373 allo<br>217 auto<br>688 chemo<br>P-value (allo vs chemo)                   | 47 (8 years)<br>42<br>34<br>0.004 | 54 (8 years)<br>49<br>42<br>0.06                   | 131       |
| AML BFM 98                     | High risk                           | 58 donor<br>166 no donor<br>P-value  | 47 (5 years)<br>41<br>0.40        | 55 (5 years)<br>54<br>0.16                         | 132       |

**Allo:** Allogeneic, **Auto:** Autologous, **DFS:** Disease Free Survival, **OS:** Overall Survival. Adapted from Klingebiel et al (133).

out-weigh the benefits. These risks have been improved for older patients in particular by using reduced-intensity chemotherapy (RIC) regimes that are non-myeloablative. The outcomes are much more promising and comparable with younger cases (134,35), although relapse rates remain a challenge (136). Data available from the European Group for Blood and Marrow Transplantation (EBMT) and the Centre for International Blood and Marrow Transplantation Research (CIBMTR) demonstrates that RIC regimens result in comparable outcomes across the adult age range (**Table 9**) (137). As raised above for chemotherapy, data is difficult to interpret for older patients due to small patient numbers, heterogeneity, and selection bias. For these reasons prospective comparison of allogeneic HSCT from matched related and unrelated donors using RIC with conventional Consolidation therapy was launched in 2008 and as of December 2011 continues to recruit to this important clinical trial (ClinicalTrials.gov Identifier: NCT00766779). The use of RIC led to concern over graft versus host effects (**Table 6**) and has prompted research into immune-suppression studies to modulate GVL and GVH reactions (138). Finally, research continues in to the benefit and most appropriate regimens using umbilical cord blood (**Table 6**) (139).

## Novel pathways and potential future agents

Several pathways and novel mechanisms of intervention are the focus of attention in current AML research.

### AKT Inhibitors

As raised in **Table 3** mTOR is a kinase involved in regulation of cell growth and proliferation. Signalling depends on its interaction through the PI3/Akt pathway (140). Both PI3K and Akt are considered to be protooncogenes. Increased membrane expression of Akt is important in initiating malignancy. It also appears to confer resistance to apoptosis through the mitogen-activated protein kinase (MAPK) pathway (141). As well as targeting mTOR (**Table 3**), Akt and MAPK inhibitors may represent new classes of drug. Perifosine is an Akt inhibitor and has shown preclinical activity against haematologic malignancies (142). Phase I and II trials have been conducted in patients with solid tumours but not in leukaemias (143). Alkylphosphocholines are lipophilic drugs that have also been shown to modulate signal transduction by their interaction with c-myc, PI3-Akt, and MAPK pathways. Erufosine, an alkylphosphocholine, has anti-leukaemic properties that warrant further exploration (144).

### RPRDX2

Studies have demonstrated that AML blasts exhibit significant lower levels of Histone H3 acetylation (H3Ac) compared to CD34+ progenitor cells. As a consequence it is suggested that a number of genes are epigenetically silenced or diminished in AML. Agrawal Singh et al (145) recently showed that Peroxiredoxin 2 (PRDX2) is a novel potential tumour suppressor gene in AML. H3Ac was decreased at the PRDX2 gene promoter in AML, and correlated with low mRNA and protein expression. Low protein expression of the antioxidant PRDX2 gene was clinically associated with poor prognosis in AML. They identified PRDX2 acts as an inhibitor of myeloid cell growth by reducing levels of reactive oxygen species (ROS) generated

**Table 9.** Comparison of EBMT and CIBMTR data in Elderly Patients

|                | n   | Median age  | RIC conditioning | OS           | Relapse Rate |                       |
|----------------|-----|-------------|------------------|--------------|--------------|-----------------------|
| <b>CIBMTR*</b> |     |             |                  |              |              |                       |
| 40-54          | 208 | 78% (p=.07) | 44% (p=0.06)     | 33% (p=0.87) | 25% (p=0.26) |                       |
| 55-60          | 146 | 68%         | 50%              | 34%          | 22%          |                       |
| 60-65          | 126 | 69%         | 34%              | 37%          | 32%          |                       |
| >65            | 55  | 65%         | 36%              | 33%          | 34%          |                       |
|                | n   | Median Age  | RIC conditioning | OS           | Relapse rate | Non-Relapse Mortality |
| <b>EBMT**</b>  |     |             |                  |              |              |                       |
| 50-60          | 884 | 54 (50-60)  | 55% (p<0.01)     | 34% (p=0.23) | 32% (p=0.02) | 36% (p=0.39)          |
| >60            | 449 | 63 (60-75)  | 78%              | 24%          | 41%          | 39%                   |

\*2 year estimates \*\*4 year estimates. Adapted from Patel et al (137).

in response to cytokines. Taken together, epigenome-wide analyses of H3Ac in AML, led to the identification of PRDX2 as an epigenetically silenced growth suppressor suggesting a possible role of ROS in the malignant phenotype in AML. This may be a pathway to explore in the application of Histone Deacetylator agents (**Table 3**).

### TET2 mutation

Over the last 2-3 years mutations of Ten-Eleven Translocation 2 (TET2), have been found in various myeloid malignancies. The gene is associated with DNA methylation, mutations leading to inhibition or reduction in appropriate myeloid cell differentiation (Chapter 2) and appears to be a prognostic biomarker in AML associated with intermediate-risk cytogenetics (146-153).

In a study last year by Weissmann et al (154) 131 somatic TET2 mutations were identified in 87/318 (27.4%) patients, and in 30% of cases of normal karyotype AML versus 19% of abnormal karyotype. Mutations of TET2 were concomitantly observed with mutations in NPM1, FLT3-ITD, FLT3-TKD, JAK2, RUNX1, CEBPA, CBL and KRAS (Chapter 2). Patients tended to be of older age, with higher haemoglobin level, higher neutrophil and monocyte counts, and lower platelet count. Similar mutational associations were identified by Chou et al (155). Survival analyses (restricted to the normal karyotype population (n=165)) in Weissmann' study showed inferior EFS in the presence of TET2 mutations.

In two other studies, one retrospective (156) the other prospective (157) the presence of TET2 mutations did not appear to influence CR or OS after standard therapy. There has also been one clinical study in higher risk MDS and AML with low blast count, where TET2 status was observed to be a genetic predictor of response to Azacitidine, independently of karyotype (141). Further clinical studies with such hypomethylating agents are warranted.

### DNMT3A mutation

DNMT3A mutations are observed in up to 22% of AML patients and appear more prevalent in the intermediate-risk groups, and especially of normal karyotype (158). The mutations are strongly associated with poor prognosis (159-161), and like TET2 are associated with decreased DNA methylation and promotion of cell differentiation. DNMT3A forms a complex with transcription factors like histone methyltransferase and histone deacetylase (162,163). Novel DNA methyltransferase and histone deacetylase inhibitors can reverse the methylomic phenotype of myeloid blasts (**Table 3** Nucleosidase and Histone Deacetylase Drugs). During therapy, early platelet response and demethylation of the FZD9, ALOX12, HPN, and

CALCA genes were associated with clinical response. Epigenetic modulation deserves prospective comparisons with conventional care in patients with high-risk AML, at least in those presenting previously untreated disease and low blast count.

## Trial methodology

### Pre-clinical

In vitro studies of cultured native AML cell lines and blasts have remarkably contributed to our current understanding on the pathogenesis of AML (**Table 10**). Well-characterised serum-free in vitro conditions are now used in experimental studies of AML, facilitating comparisons between different experiments. Assays for characterisation of AML progenitor subsets such as suspension cultures, colony assays, long-term in vitro culture, xenotransplantation in immunocompromised mice, as well as, AML cell lines as experimental models have been used to increase our knowledge on pathogenesis of AML (164). Furthermore, biomarker studies suggest that the in vitro growth characteristics of AML blasts assayed by short-term culture of the total native populations can be used as a predictor of prognosis after intensive chemotherapy. In vitro assays may be used for more accurate identification of prognostic parameters and for creation of a basis for the development of simplified laboratory techniques suitable for routine evaluation of patients undergoing risk-adapted therapy (164).

### Clinical

Drug development processes are lengthy and costly. While the phase I-III sequence of clinical drug testing has remained intact for decades, it appears inherently inefficient and the high frequency of false-positive results obtained in phase II studies constitutes a significant scientific concern (175-180). The sequential trial scheme puts major emphasis on such studies because they typically inform the decision to proceed to a phase III evaluation (175). Strategies to mitigate shortcomings caused by lack of control groups, patient heterogeneity, selection bias, and choice of end points and strategies for streamlining trial design have been suggested. Such enhancements would among others encompass larger phase II studies, inclusion of (preferably randomised) controls, consideration of integrated phase 2/3 studies, accounting for patient heterogeneity even in small randomised studies, provision of information about the number of patients available for study vs. those actually treated, and avoidance of unvalidated alternate endpoints and premature publication (**Table 11**) (175).

**Phase I trials** often provide novel agents to patients with relapsed and refractory disease (181). It has been argued that

**Table 10.** Experimental models for the study of AML cell proliferation.

| Experimental model  | Description of the experimental procedure   | Dominating phenotype of proliferating cells  | Comments   |
|---|---|--|--|
| Short-time suspension culture with 3H-thymidine incorporation | The total population of native AML cells cultured for six to seven days before nuclear radioactivity is determined (165).   | Probably clonogenic cells of the phenotype CD34- (167-169).  | Reflects an enrichment of colony-forming cells, and assays the response of a subset of AML cells able to proliferate after one week of in vitro culture (168). Regarded as more sensitive than the colony (170).   |
| Primary colony formation                                      | Native AML cells seeded directly in a colony-forming assay (166-168).   | Fluorouracil-sensitive CD34- cells (171).  | Depending on the culture conditions (medium alone or addition of exogenous cytokines), colonies can be differentiated into small abnormal clusters of uniform morphology, blast-like/monocytic and erythroid colonies (172). Colony-forming cells are a minority among native AML cells (usually <3%) (169). |
| Long-term suspension culture                                  | Culture of AML cells in suspension culture for two to eight weeks before the number of colony-forming cells in the population is estimated (166, 168).  | CD34+CD71-CD90-HLA-DR- for most patients; in exceptional patients CD34- (166, 172).                              | The frequency of suspension culture initiating cells (SCIC) is usually lower than the frequency of primary colony-forming cells (168).   |
| Cobblestone-area forming cells                                | Suspension culture of AML cells on a stromal layer in the presence of exogenous cytokines; the number of colonies with cobblestone morphology is determined after several weeks of culture (170). | Fluorouracil-resistant progenitors (170).  | The most primitive cobblestone-area forming cells (week 6) are less sensitive to Fluorouracil than less primitive (week 2) cells The frequency of these progenitors seems comparable to the suspension-culture initiating cells (170).   |
| SCID mouse repopulating cells                                 | A xenotransplant model with engraftment of AML cells in combined immunodeficient mice (172).  | Usually CD34+CD71-CD90-HLA-DR-, in exceptional patients CD34- cells. The cells are Fluorouracil resistant (170). | The most effective SCID-repopulating cells constitute a small minority of CD34+CD38-HLA-DR- cells among native AML blasts The number of cells needed for engraftment varies between patients (173-174).  |

Adapted from Bruserud Ø et al. (164).

noncytotoxic, molecularly targeted agents have not been very successful in this setting. Thus, signals of their true biologic efficacy may be missed and consequently potentially useful agents seem fail to demonstrate a signal of efficacy in the phase I setting. It has been proposed that at least some of these compounds should be considered instead in trials to prolong response duration (181).

**Phase II trials** in AML are usually small-scale and may give misleading efficacy signs (175, 166). Due to the heterogeneity of the disease, subset analyses based at least on age, performance status, cytogenetics, and molecular features are necessary (175). However, these are meaningless when the total group includes a small number of patients (181). Consequently, there is increasing support for randomised phase II trials strategies planned to quickly compare new treatments with existing standards using as few patients as possible and to proceed only with those that meet predetermined efficacy benchmarks (181).

**Phase III trials** in AML are often slow, expensive to complete and, regrettably, often resulting in minor improvements. It

has also become increasingly difficult to determine a feasible control group for new phase 3 trials due to the large number of molecularly and clinically defined subgroups. Further enhancements in the molecular characterisation of AML could allow the identification of more homogeneous treatment cohorts and tailored therapeutics (181).

### Translational strategies to accelerate drug development

- Focusing on development of existing drugs in addition to searching for new ones.** Due to the heterogeneous pathogenesis and molecular genetics of AML, tailored, personalised treatment based on the specific biologic features of the leukemic cells should be the objective. This also indicates that combination therapy is likely to remain superior to any single compound (181). One interesting suggestion is to use the gene-expression signature generated from drugs that effectively ablate LSCs to study publicly available databases for other similar signatures (182). In the case of "off-patent agents" , this could possibly al-

**Table 11.** Suggestions for improvements of clinical trial designs in AML.

| Problem   | Possible solution   |
|---|---|
| Cost and inefficiency of oncology drug development, especially in phase II/III trials | More attention should be given to the conduct of phase II trials to minimise the risk of overly optimistic reporting of results and to limit the number of subsequent negative phase III trials. Creation of better strategies for identification of phase II trial characteristic that predict a positive phase III study. Focus on characteristics in trial design may help optimise drug development and minimise the resources expended on drugs that will likely fail in later stages of drug testing. |
| High false-negative and false-positive rates  | Increase in study sizes. To properly interpret the results of phase II studies, scientific reports should specify the false-positive and false-negative errors associated with number of patients treated; furthermore, for studies that use the experience of previously untreated or differently treated patients as a basis for comparison, the number of such patients along with their distribution of clinical characteristics should be provided.  |
| Ill-defined historical control group  | Explicit description of the control group (number of patients, type of study, diagnoses, treatment); adjustments for sampling variation and differences in case mix.  |
| Lack of control group makes it difficult to estimate how good results truly are       | Use of explicitly described historical or concurrent control group; randomization, including multi-arm, multi-stage designs.  |
| Handling patient heterogeneity  | Stratified trial; statistical adjustment (multivariate analysis).   |
| General is ability of treatment results, effect modification                          | Explicit description of inclusion/exclusion criteria, provision of information about total number of patients available for study vs. those actually treated.   |
| Choice of surrogate endpoint that does not predict clinical benefit                   | Use of validated surrogates; validation of alternative endpoints before use.  |
| Delay in activation of phase III trial  | Integrated phase II/III trial design; streamlining of internal and external groups and processes. Adaptive trial design.  |
| Bias through early publication  | Allowance of adequate follow-up time between completion of study accrual and publication; introduction of journal policies to discourage too early publication.   |

Adapted from Walter RB et al. (175).

low existing agents with well-identified clinical profiles and easy availability, to rapidly lead into AML treatments (181).

- Increasing participation in clinical trials.** Less than 5% of adult cancer patients in US participate in clinical trials, contrary to 60% of paediatric cancer patients (181,183). Recently, a French survey reported that 25% of AML patients among 1066 adults with AML were enrolled in clinical trials (181,184). Physician and patient education about clinical trials should be enhanced and collaboration between academic centers and cooperative groups should be improved (181). Increasing accrual in clinical trials is vital, as there the traditional phase I-III drug-development paradigm seems ineffective in this disease (175,181).
- Improving of safety and efficiency.** Implementing biomarkers in clinical trials may improve decision-making in drug development process (185). Biomarkers predicting therapeutic response enable the selection of patients most likely to have positive treatment outcomes with a particular oncologic therapy. Predictive pharmacogenomic biomark-

ers, enabling selective treatment, are likely to become increasingly common in future therapies (186). Biomarkers predicting the safety of a compound are highly valuable for preclinical testing, or early clinical studies. Microdosing studies could be used for improving safety when evaluating drug candidates at early stage development. Adaptive trial designs in AML studies could improve safety and efficacy by providing opportunities to make changes to a study in response to accumulating data whilst maintaining the trial's integrity and validity.

## Conclusion

AML is characterised by a multitude of chromosomal abnormalities and gene mutations, which translate to marked differences in responses and survival following chemotherapy, radiotherapy and HSCT. These chromosomal and genetic abnormalities make the treatment of AML challenging. The limit of acceptable toxicity for standard chemotherapeutic drugs used in AML therapy has been reached. A detailed under-

standing of the molecular changes associated with chromosomal and genetic abnormalities is necessary to pilot new therapy design. Although several deregulated proteins and genes have been identified, their diversity among AML patients have made it difficult to identify a single substance that can hit these diverse targets. New agents have shown promise but there remains a huge need to be met for effective and targeted therapies to be successful.

## References

1. Thomas ED, Buckner CD, Banaji M *et al.*: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. *Blood*. 1977;49:511-533.
2. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. *Pharmacol Ther.* 2000;87(2-3):227-53.
3. Faduola P. Stem cell transplantation in acute myeloid leukemia; history, drivers and challenges. *Int J Biol Med Res.* 2012; 3(3): 2132-2137
4. Kaspers, G. & Creutzig, U. Pediatric AML: long term results of clinical trials from 13 study groups worldwide. *Leukemia.* 2005;19:2025-146
5. Foran, J.M. New prognostic markers in acute myeloid leukemia: perspective from the clinic. *Hematology Am Soc Hematol Educ Program*, 2010, pp47-55.
6. Godley, L.A., Cunningham, J., Dolan, M.E., *et al.* An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. *Semin Oncol.* 2011; 38(2):215-24.
7. Zmorzyski, S., Filip, A.A., Koczkodaj, D. & Michalak, M. Molecular and cytogenetic prognostic factors in acute myeloid leukemia (AML). *Postepy Hig Med Dosw.* 2011;21(65):158-66
8. (160)Walter RB, Appelbaum FR, Tallman MS *et al.* Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. *Blood.* 2010;116(14):2420-28
9. Lobo, P.J., Powles, R.L., Hanrahan, A. & Reynold, D.K. (1991). Acute myeloblastic leukaemia - a model for assessing value for money for new treatment programmes. *BMJ*, 302(6772):323-26.
10. Dufoir, T., Saux, M.C., Terraza, B., *et al.* Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. *Bone Marrow Transplant.* 1992;10(4):323-29.
11. Creutzig, U., & Kaspers, G.J.L. (. Editorial: Pediatric acute myeloid leukemia: international progress and future directions. *Leukemia.* 2005;19:2025-2029
12. Bensinger WI, Weaver CH, Appelbaum FR, *et al.* Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. *Blood.* 1995; 85(6):1655-1658.
13. Ljungman P, Bregni M, Brune M, *et al.* Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. *Bone Marrow Transplant.* 2010; 45(2):219-234
14. Nataliya Kuptsova, Kenneth J. Kopecky, John Godwin, Jeanne Anderson, Ashraf Hoque, Cheryl L. Willman, Marilyn L. Slovak, and Christine B. Ambrosone. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. *Blood.* 2007 109: 3936-3944
15. Buccisano F, Maurillo L, Gattei V, *et al.* The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. *Leukemia.* 2006;20(10):1783-1789.
16. Maurillo L, Buccisano F, Spagnoli A, *et al.* Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. *Haematologica.* 2007;92(5):605-611
17. Castagnola C, Nozza A, Corso A, Bernasconi C. The value of combination therapy in adult Acute Myeloid Leukemia with central nervous system involvement. *Haematologica* 1997; 82:577-580
18. Gibson BE, Webb DK, Howman AJ, *et al.* Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML 12 trial. *Br J Haematol.* 2011;155(3):366-76.
19. Sekeres MA, Elson P, Kalaycio ME, *et al.* Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. *Blood.* 2009;113(1):28-36.
20. Löwenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. *Hematology Am Soc Hematol Educ Program.* 2003:82-101.

21. Estey E, Döhner H. Acute myeloid leukaemia. *Lancet*. 2006;368(9550):1894-1907.
22. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. *Blood*. 2006;107(9):3481-5.
23. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. *J Clin Oncol*. 2007;25(14):1908-15.
24. Farag SS, Archer KJ, Mrózek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. *Blood*. 2006;108(1):63-73.
25. Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are the main determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. *Blood*. 2006;108(10):3280-38.
26. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. *Cancer*. 2007;109(6):1114-24.
27. Fenaux P, Lai JL, Gardin C, Bauters F. Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly [letter]. *Leukemia*. 1990;4(4):312.
28. Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. *Leukemia*. 2004;18(4):809-16.
29. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. *J Clin Oncol*. 1992;10(7):1103-11.
30. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. *Leukemia*. 1991;5(6):510-6.
31. Berman E, Arlin ZA, Gaynor J, et al. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. *Leukemia*. 1989;3(2):115-21.
32. Arlin Z, Case DC Jr., Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). *Leukemia*. 1990;4(3):177-83.
33. Rowe JM, Neuberg D, Friedenber W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. *Blood*. 2004;103(2):479-85.
34. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. *Blood*. 2002;100(12):3869-76.
35. Gardin C, Turlure P, Fagot T, et al. Post-remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. *Blood*. 2007;109(12):5129-35.
36. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. *Blood*. 1996;88(8):2841-51.
37. Bishop JF, Matthews JP, Young GA, et al. Randomized study of high-dose cytarabine in induction in acute myeloid leukemia. *Blood*. 1996;87(5):1710-7.
38. Cassileth PA, Lee SJ, Litzow MR, et al. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). *Leuk Lymphoma*. 2005;46(1):55-61.
39. Petersdorf SH, Rankin C, Head DR, et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). *Am J Hematol*. 2007;82(12):1056-62.
40. Büchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and post-remission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. *J Clin Oncol*. 2006;24(16):2480-9.
41. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. *N Engl J Med*. 2009;361(13):1235-48.
42. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. *Blood*. 1990;75(1):27-32.
43. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10<sup>th</sup> AML trial (MRC AML10). *Blood*. 1997;89(7):2311-8.
44. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C, fludarabine + ara-C, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. *Blood*. 2001;98(13):3575-83.
45. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. *Blood*. 2004;103(8):2908-13.
46. Milligan DW, Wheatley K, Littlewood T, Craig JIO, Burnett AK. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. *Blood*. 2006;107(12):4614-22.
47. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. *Blood*. 2001;98(12):3212-20.
48. Estey EH. Growth factors in acute myeloid leukaemia. *Best Pract Res Clin Haematol*. 2001;14(1):175-87.
49. Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. *N Engl J Med*. 2003;349(8):743-52.
50. Thomas X, Raffoux E, de Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. *Leukemia*. 2007;21(3):453-61.
51. Büchner T, Berdel WE, Hiddemann W. Priming with granulocyte colony stimulating factor - relation to high-dose cytarabine in acute myeloid leukemia [comment]. *N Engl J Med*. 2004;350(21):2215-6.
52. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. *N Engl J Med*. 1994;331(14):896-903.
53. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. *Cancer Res*. 1998;58(18):4173-9.
54. Elonen E, Almqvist A, Hänninen A, et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. *Leukemia*. 1998;12(7):1041-8.
55. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. *Lancet*. 1998;351(9104):700-8.
56. Stone RM, Berg DT, George SL, et al. Post-remission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. *Blood*. 2001;98(3):548-53.

57. Büchner T, Hiddemann W, Berdel WE, et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. *J Clin Oncol*. 2003;21(24):4496-504.
58. Weisser M, Hafelach C, Hiddemann W, Schittgers S. The quality of molecular response to chemotherapy is predictive for outcome of AML1-ETO positive AML and is independent of pretreatment risk factors. *Leukaemia*. 2007;21(6):1771-82.
59. Schlenk RF, Fröhling S, Hartmann F, et al. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial [letter]. *Leukemia*. 2006;20(4):748-50.
60. Latagliata R, Breccia M, Fazi P, et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. *Br J Haematol*. 2008;143(5):681-9.
61. Lim WS, Tardi PG, Dos Santos N, et al. Leukaemia-selective uptake of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation in bone marrow xenografts. *Leuk Res*. 2010;34(9):1214-23.
62. Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE. Liposomal encapsulation of a synergistic molar ration of cytarabine and daunorubicin enhances selected toxicity for acute myeloid leukaemia progenitors compared to component analogue normal haemopoietic cells. *Exp Hematol*. 2011;39(7):741-50.
63. O'Brien S, Rizzieri DA, Vey N, et al. A phase II multicentre study with elecytarabine as secondary salvage therapy in patients with AML. *J Clin Onc*. 2009; 27:15s(suppl; abstr 1042).
64. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. *Blood*. 2001;97(10):3197-204.
65. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. *J Clin Oncol*. 2001;19(13):3244-54.
66. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. *Blood*. 2003;102(13):4277-83.
67. Stasi R, Evangelista ML, Buccisano F, et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. *Cancer Treat Rev*. 2008;34:49-60.
68. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. *Blood*. 1999;93:3678-84.
69. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukaemia. *Clin Cancer Res*. 2004;10(11):3577-85.
70. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. *Cancer Cell*. 2002;1(5):433-43.
71. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. *Blood*. 2002;99(11):3885-91.
72. O'Farrell A-M, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. *Blood*. 2003;101(9):3597-3605.
73. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. *Blood*. 2005;105(1):54-60.
74. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. *Blood*. 2004;103(10):3669-76.
75. Heidel F, Cortes J, Rucker FG, et al. Results of a multi-centre phase II trial for older patients with c-KIT-positive acute myeloid leukaemia and high-risk myelodysplastic syndrome using low-dose Ara-c and Imatinib. *Cancer*. 2007;109(5):907-14.
76. Giles FJ, Bellamy WT, Estrov Z, et al. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukaemia or myelodysplastic syndrome. *Leuk Res*. 2006;30(7):801-11.
77. Yee KE, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus in patients with relapsed or refractory hematological malignancies. *Clin Cancer Res*. 2006;12(17):5165-73.
78. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus, a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematological malignancies. *Clin Cancer Res*. 2008;14(9):2752-79. Karp JE, Flatten K, Feldman EJ, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukaemia: a preclinical and phase I trial of tipifarnib combined with etoposide. *Blood*. 2009;113(20):4841-52.
80. Ravoet C, Mineur P, Robin V, et al. Farnesyl transferase inhibitor (lonofarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. *An Hematol*. 2008;87(11):881-5.
81. Cortes J, Faderl S, Estey E, et al. A phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukaemias and myelodysplastic syndromes. *J Clin Oncol*. 2005;23(12):2805-12.
82. Fiedler W, Serve H, Döhner H, et al. A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. *Blood*. 2005;105(3):986-93.
83. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. *J Clin Oncol*. 2002;20(10):2429-40.
84. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. *J Clin Oncol*. 2000;18(5):956-62.
85. Issa J-P, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood*. 2004;103(5):1635-40.
86. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-32.
87. Burnett AK, Baccharani M, Johnson P. Effectiveness of clofarabine in elderly AML patients with adverse cytogenetics unfit for intensive chemotherapy. *Blood*. 2006;108:1985a.
88. Burnett AK, Russell NH, Kell J, et al. European development of Clofarabine as treatment for older patients considered unsuitable for induction chemotherapy. *J Clin Onc*. 2010;28:2389-95.
89. Giles FJ, Cortes JE, Baker SD, et al. Troxacitabine, a novel dioxolone nucleosidase analogue, has activity in patients with advanced leukaemia. *J Clin Oncol*. 2001;19:762-71.
90. Roboz GJ, Giles FJ, Ritchie EK, et al. Phase I/II study of continuous infusion Troxacitabine in refractory AML. *J Clin Oncol*. 2006;25:10-15.
91. Garcia-Manero G, Luger S, Vemigopal P, et al. A randomized phase II study of sapacitabine in elderly patients with AML previously untreated or in first relapse or previously treated MDS. *J Clin Oncol*. 2009; 27:15s(Suppl;abstr. 7021).
92. Giles FJ, Stock W, Vey N, et al. A double-blind placebo-controlled randomized phase III study of high dose araC with or without clometazine in patients with first relapse of acute myeloid leukaemia. *Blood*. 2006; 108:(Suppl, abstr. 1970).

93. Yang LP, Perry CM. Histamine dihydrochloride in the management of acute myeloid leukaemia. *Drugs*. 2011;71(1):109-22.
94. Bug G, Ritter M, Wassmann B, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. *Cancer*. 2005;104(12):2717-25.
95. Raffoux E, Cras A, Recher C, et al. Phase 2 clinical trial of Azacitidine, valproic acid and all trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. *Oncotarget*. 2010;1(1):34-42.
96. Burnett AK, Milligan D, Goldstein A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. *Br J Haematol*. 2009;145(3):318-32.
97. Lancet JE, Baer MR, Duran GE, et al. A phase I trial of continuous infusion of the multidrug resistant inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukaemia. *Leuk Res*. 2009;33(8):1055-61.
98. Schmitt M, Casalegno-Garduño R, Xu X, Schmitt A. Peptide vaccines for patients with acute myeloid leukemia. *Expert Rev Vaccines*. 2009;8(10):1415-25.
99. Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR-1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. *Blood*. 2004;104:259 (Abstract).
100. Qazilbash MH, Wieder E, Thall PF, et al. PR-1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response event-free survival. *Blood*. 2007;110:577 (abstract).
101. Schmitt M, Schmitt A, Rojewski M, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. *Blood*. 2008;11:1357-65.
102. Giannopoulos K, Kowal M, Dmoszynska A, et al. Peptide vaccination induces dynamic changes in CD4<sup>+</sup> and CD8<sup>+</sup> cell subsets: report on the first peptide vaccination trial in patients with chronic lymphocytic leukemia (CLL). *Blood*. 2008;112:3159 (abstract).
103. Greiner J, Schmitt A, Giannopoulos K, et al. High-dose RHAMM-R3 peptide vaccination for patients with vaccination for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). *Blood*. 2008;112:2911(abstract).
104. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic Phase 2 trial of Wilms tumor gene product 1 (WT-1) peptide vaccination in patients with AML and MDS. *Blood*. 2009;113:6541-8.
105. Mailander V, Scheibenbogen C, Thiel E, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT-1 peptide in the absence of haematological or renal toxicity. *Leukemia*. 2004;18:165-6.
106. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT-1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT-1 peptide vaccine and the resultant cancer regression. *Proc. Natl Acad. Sci. USA*. 2004;101:13885-90.
107. Rezvani K. PR-1 vaccination in myeloid malignancies. *Expert Rev Vaccines*. 2008;7(7):867-75.
108. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR-1 and WT-1 peptide vaccination in patients with myeloid malignancies. *Blood*. 2008;111:236-42.
109. Wagner EM, Kuball J, Wattad M, Huber C, Heit W, Theobald M. Vaccination with WT-1 and PR-3 derived peptides in patients with AML/MDS and MUC1 peptides in patients with multiple myeloma - preliminary results. *Blood*. 2008;108:4582.
110. Brenner MK. The contribution of marker gene studies to hemopoietic stem cell therapies. *Stem Cells*. 1995;13(5):453-61.
111. Jacob H, Hube A. Preservation of stem cells. *Organogenesis*. 2009;5(3):134-7.
112. Riggs JR, Wanta SM, Letic N, Craig MJ, Gallicano GI. Current and prospective therapies to treat leukaemia. *Journal of Hematological Malignancies*. 2011;1(1):24-34.
113. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. *Blood*. 2000;96(13):4075-83.
114. Schlenk RF, Benner A, Hartmann F, et al. Risk adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial. *Leukemia*. 2003;17(8):1521-8.
115. Breems DA, Löwenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. *Semin Hematol*. 2007;44(4):259-66.
116. Whitman SP, Ruppert AS, Marcucci G, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. *Blood*. 2007;109(12):5164-7.
117. Horowitz MM, Gale RP, Sondel PM. Graft-versus-leukemia reactions after bone marrow transplantation. *Blood*. 1990;75(3):555-62.
118. Cornelissen JJ, van Putten WLJ, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? *Blood*. 2007;109(9):3658-66.
119. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. *Cancer*. 2005;103(8):1652-8.
120. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA*. 2009;301(22):2349-61.
121. Reiffers J, Gaspard MH, Maraninchi D, et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. a prospective controlled trial. *Br J Haematol*. 1989;72:57.
122. Lowenberg B, Verdonck LJ, Dekker AW, et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. *Journal of Clinical Oncology*. 1990;8(2) 287-94.
123. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA). *N Engl J Med*. 1995;332(4):217-23.
124. Harousseau JL, Cahn J, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukaemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). *Blood*. 1997;90:2978-86.
125. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. *N Engl J Med*. 1998;339(23):1649-56.
126. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. *Lancet*. 1998;351:700.
127. Blume KG, Thomas ED. A Review of Autologous Hematopoietic Cell Transplantation. *Bio Blood Marrow Transplant*. 2000;6(1):1-12.
128. Ortega JJ, Diaz de Heredia C, Olive T, et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. *Haematologica*. 2003;88:290-9.
129. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. *Blood*. 2001;97:56-62.
130. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's

- 10<sup>th</sup>AML trial. MRC Childhood Leukaemia Working Party. *Br J Haematol*.1998;101:130-40.
131. Alonzo TA, Wells RJ, Woods WG, et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era. *Leukemia*. 2005;19:965-70.
  132. Reinhardt D, Kremens B, Zimmermann M, et al. No improvement of overall-survival in children with high-risk acute myeloid leukemia by stem cell transplantation in 1<sup>st</sup> complete remission. *Blood*. 2006;108:99a.
  133. Klingebiel T, Reinhardt D, Bader P. Place of HSCT in treatment of childhood AML. *Bone Marrow Transplantation*. 2008;42:S7-S9.
  134. Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the Cooperative German Transplant Study Group. *J Clin Oncol*. 2008;26(32):5183-91.
  135. Boglarka Gyurkocza, Frederick R. Appelbaum. Identifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantation. *Natl Compr Canc Netw*. 2011(9):319-30.
  136. Lee SE, Lim J, Yahng SA, et al. Reduced-intensity conditioning regimen combined with low-dose total body irradiation in the treatment of myelodysplastic syndrome. *Acta Haematol*. 2011;126(1):21-9.
  137. Patel P, Saraf S, Rondelli D. Allogeneic stem cell transplantation to cure acute myeloid leukaemia in elderly patients. *Journal of Advances in Internal Medicine*. 2012;1(1):43-9.
  138. Morecki S, Yacovlev E, Gelfand Y, Shabat Y, Slavin S. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators. *Biol Blood Marrow Transplant*. 2009;15(15):406-15.
  139. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. *Blood*. 2010;116(22):4693-9.
  140. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumorigenesis and targeted antitumour therapy. *Cell Mol Biol Lett*. 2005;10(3):479-98.
  141. Park S, Chapuis N, Tamburini J, et al. Role of PI3K/AKT and mTOR signalling pathways in acute myeloid leukaemia. *Haematologica*. 2010;95(5):819-28.
  142. Gills JJ, Dennis PA. Perifosine: update on a novel AKT inhibitor. *Curr Oncol Rep*. 2009;11(2):102-110.
  143. Crul M, Rosing H, de Klerk, et al. Phase I and pharmacological study of daily oral administration of perifosine in patients with advanced solid tumours. *Eur J Cancer*. 2002;38(12):1615-21.
  144. Fiegl M, Lindner LH, Juergens M, Eibl H, Hiddemann W, Braess J. Erofusine, a novel alkylphosphocholine, in acute myeloid leukaemia: single activity and combination with other antileukaemic drugs. *Cancer Chemother Pharmacol*. 2008;62(2):321-9.
  145. Agrawal-Singh S, Isken E, Agelopoulos K, et al. Genome wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. *Blood*. 2012;119(10):2346-57.
  146. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. *Nat Genet*. 2009;41(7):838-42.
  147. Tefferi A, Lim KH, Levine R. Mutation in TET2 in myeloid cancers. *N Engl J Med*. 2009;361(11):1117.
  148. Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. *Blood*. 2010;116(7):1132-5.
  149. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell*. 2010;18(6):553-67.
  150. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. *Nature*. 2010;466(7310):1129-33.
  151. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. *Cancer Cell*. 2011;20(1):11-24.
  152. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. *Blood*. 2011;118(17):4509-18.
  153. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell*. 2012;20(1):25-38.
  154. Weissman S, Alpermann T, Grossmann V, et al. Landscape of TET2 Mutations in acute myeloid leukaemia. *Leukemia*. 2011;Nov25:doi:10.1038/leu.2011.326.
  155. Chou W-C, Chou S-C, Liu C-Y, et al. TET2 mutation is an unfavourable prognostic factor in acute myeloid leukemia patients with intermediate risk cytogenetics. *Blood*. 2011;118(14):3803-10.
  156. Kosmider O, Delabesse E, Mansat-De Mas V, et al. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. *Haematologica*. 2011;96(7):1059-63.
  157. Gaidzik VI, Paschka P, Spath D, et al. TET2 Mutations in Acute Myeloid Leukemia (AML): Results from a comprehensive genetic and clinical analysis of the AML Study Group. *J Clin Oncol*. 2012, March19:doi: 10.1200/JCO.2011.39.2886.
  158. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. *Leukemia*. 2011;25(7):1147-52.
  159. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. *N Engl J Med*. 2010;363(25):2424-33.
  160. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. *Nat Genet*. 2011;43(4):309-15.
  161. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. *Blood*. 2011;118(20):5593-603.
  162. Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. *J Clin Oncol*. 2011;29(21):2889-96.
  163. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. *Nature*. 2006;439(7078):871-4.
  164. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. *Nat Rev Genet*. 2009;10(5):295-304.
  165. Bruserud Ø, Gjertsen BT, Foss B, Huang T. New Strategies in the Treatment of Acute Myelogenous Leukemia (AML): In Vitro Culture of AML Cells---The Present Use in Experimental Studies and the Possible Importance for Future Therapeutic Approaches. *Stem Cells*. 2001;19:1-11.
  166. Bruserud Ø, Gjertsen BT, Brustugun OT, et al. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. *Leukemia*. 1995;9:1910-20.
  167. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+CD71-/HLA-DR-. *Blood*. 1998;92:4325-35.
  168. Nara N, McCulloch EA. The proliferation in suspension of the progenitors of the blast cells in acute myeloblastic leukemia. *Blood*. 1985;65:1484-93.
  169. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. *Blood*. 1996;87:4754-61.

170. Delwel R, Salem M, Pellens C, et al. Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. *Blood*. 1988;72:1944-49.
171. Terpstra W, Ploemacher RE, Prins A et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. *Blood*. 1996;88:1944-50.
172. Bruserud Ø, Gjertsen BT, von Volkman HL. In vitro culture of human acute myelogenous leukemia (AML) cells in serumfree media; studies of native AML blasts and AML cell lines. *J Hematother Stem Cell Res*. 2000;9(6):923-32.
173. Dick JE. Human stem cell assays in immunodeficient mice. *Curr Opin Hematol*. 1996;3:405-9.
174. Blair A, Hogge DE, Ailles LE et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. *Blood*. 1997;89:3104-12.
175. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71-/HLA-DR-. *Blood*. 1998;92:4325-35.
176. Rombouts WJC, Martens ACM, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCIDhuman chimera model. *Leukemia*. 2000;14:889-97.
177. Walter RB, Appelbaum FR, Tallman MS et al. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. *Blood*. 2010;116(14):2420-28.
178. Estey EH, Thall PF. New designs for phase 2 clinical trials. *Blood*. 2003;102(2):442-8.
179. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. *J Clin Oncol*. 2005;23(28):7199-206.
180. Berry DA. Bayesian clinical trials. *Nat Rev Drug Discov*. 2006;5(1):27-36.
181. Sonpavde G, Galsky MD, Hutson TE, Von Hoff DD. Patient selection for phase II trials. *Am J Clin Oncol*. 2009;32(2):216-9.
182. Hunsberger S, Zhao Y, Simon R. A comparison of phase II study strategies. *Clin Cancer Res*. 2009;15(19):5950-5.
183. Gail J. Roboz. Novel Approaches to the Treatment of Acute Myeloid Leukemia. *Hematology Am Soc Hematol Educ Program*. 2011;1:43-50.
184. Hassane DC, Guzman ML, Corbett C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. *Blood*. 2008;111(12):5654-62.
185. Lara PN, Jr., Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. *J Clin Oncol*. 2001;19(6):1728-33.
186. Dechartres A, Chevret S, Lambert J, Calvo F, Levy V. Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases. *Ann Oncol*. 2011;22(1):224-33.
187. De Gruttola VG, Clax P, DeMets D et al. Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials: Summary of a National Institutes of Health Workshop. *Clin Trials*. 2001;22:485-502.
188. Swen JJ, Huizinga TW, Gelderblom H, et al. Translating Pharmacogenomics: Challenges on the Road to the Clinic. *PLoS Med*. 2007;4(8):e209

## Follow us:



**Medicalia.org**

Where Doctors exchange clinical experiences, review their cases and share clinical knowledge. You can also access lots of medical publications for free. **Join Now!**

<http://medicalia.ning.com/>

## Publish with iMedPub

<http://www.imedpub.com>

- ✓ Translational Biomedicine (TBM) is an international, peer-reviewed, Open access journal with world famous scientist on the editorial board.
- ✓ TBM publishes high quality articles from all areas and fields which have an impact to understand human biology, pathogenesis, diagnosis and treatment for human diseases.
- ✓ Event's proceedings and abstracts are also published.
- ✓ TBM welcomes researchers and experts from clinical side to submit their manuscripts for rapid publication.

**Submit your manuscript here:**

<http://www.transbiomedicine.com>